Table 2.
Univariable and multivariable analyses for local failure.
| Univariable Analysis | Multivariable Analysis | |||
|---|---|---|---|---|
| Variables | HR (95% CI) | p-Value | HR (95% CI) | p-Value |
| Age | 1.02 (0.99, 1.04) | 0.156 | ||
| Sex | 0.022 | 0.008 | ||
| Male | Reference | Reference | ||
| Female | 0.64 (0.43, 0.94) | 0.35 (0.16, 0.76) | ||
| Primary tumor histology | 0.411 | |||
| Other | Reference | |||
| Lung | 1.60 (0.84, 3.04) | |||
| Breast | 1.28 (0.53, 3.14) | |||
| Gastroinestinal | 0.81 (0.26, 2.50) | |||
| Total number of brain metastases treated per SRS course | 0.97 (0.90, 1.04) | 0.374 | ||
| Extracranial disease | 0.006 | 0.016 | ||
| Yes | Reference | Reference | ||
| No | 0.45 (0.22, 0.92) | 0.17 (0.40, 0.72) | ||
| Status of extracranial disease | 0.251 | |||
| Stable | Reference | |||
| Progressive | 1.24 (0.86, 1.80) | |||
| KPS | 1.01 (0.97, 1.05) | 0.773 | ||
| Immobilization method | 0.290 | 0.518 | ||
| Mask | Reference | Reference | ||
| Frame | 0.81 (0.55, 1.19) | 0.52 (0.24, 1.14) | ||
| SRS prescription dose | 0.336 | |||
| 24 Gy | Reference | |||
| 22 Gy | 1.26 (0.77, 2.04) | |||
| Tumor maximal diameter | 1.33 (0.52, 3.38) | 0.561 | ||
| Tumor volume | 1.16 (0.63, 2.14) | 0.636 | ||